Alex Balcom is currently chief financial officer of Nuvalent. Prior to joining Nuvalent, she served as vice president of finance at SQZ Biotechnologies, where she helped raise more than $200 million in private and public equity financing, including the company’s 2020 initial public offering. Previously, Ms. Balcom served as corporate controller at Agios Pharmaceuticals, supporting more than $700 million in equity financing. She earned a BBA in finance from the University of Massachusetts, Amherst, and an MBA from Boston College. She is also a certified public accountant in Massachusetts.